Monitor for patient enrollment commencement and any early data readouts, which are the next key catalysts. The stock has historically shown large moves on operational updates, but this filing alone is a routine milestone with no clinical results. Traders should watch for enrollment timing announcements tied to allergy seasons.
Price Chart
Executive Summary
Polyrizon announced it has completed contracting with all five U.S. clinical sites for its first-in-human study of NASARIX (PL-14), a non-drug nasal spray for seasonal allergic rhinitis. The study is designed to enroll up to 120 patients and is advancing toward patient pre-screening and enrollment, which will be timed with allergy seasons. This is an operational milestone for a development-stage company, but no clinical data or revenue is generated yet, and the stock has historically shown high volatility on such news.
Key Facts
- Completed contracting with all five U.S. clinical sites for the NASARIX (PL-14) study.
- First-in-human, prospective, multicenter, randomized, single-blind, two-arm clinical trial.
- Designed to enroll up to 120 patients with seasonal allergic rhinitis.
- Primary endpoint: mean daily reflective Total Nasal Symptom Score (rTNSS) over first 14 days.
- Enrollment timed to coincide with relevant allergy seasons; no start date given.
- Company is a development-stage biotech with no approved products or revenue.
Financial Impact
No financial figures disclosed; pre-revenue development-stage company.
Risk Factors
- No clinical data yet; study may fail to meet endpoints.
- Enrollment delays due to seasonal timing or recruitment challenges.
- Pre-revenue company with high cash burn and potential need for additional financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-092083 |
| Document: ea0302853-6k_polyrizon.htm | 0001213900-26-092083 |
| Document: 0001213900-26-092083-index-headers.html | 0001213900-26-092083 |
| Document: 0001213900-26-092083-index.html | 0001213900-26-092083 |
| Document: 0001213900-26-092083.txt | 0001213900-26-092083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.96 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers